The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
대표청구항▼
1. An isolated antibody that binds to C10orf54, wherein the antibody is selected in the group consisting of: 1) an antibody having(a) a heavy chain variable (VH) region comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOS: 33, 34, and 35,(b) a light chain
1. An isolated antibody that binds to C10orf54, wherein the antibody is selected in the group consisting of: 1) an antibody having(a) a heavy chain variable (VH) region comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOS: 33, 34, and 35,(b) a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOS: 42, 43, and 44;2) an antibody having(a) a heavy chain variable (VH) region comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOS: 1117, 1118, and 1119,(b) a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOS: 1120, 1121, and 44;3) an antibody having(a) a heavy chain variable (VH) region comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOS: 1122, 34, and 35,(b) a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOS: 42, 43, and 44;4) an antibody having(a) a heavy chain variable (VH) region comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOS: 1123, 1124, and 1125,(b) a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOS: 1126, 1121, and 1127;5) an antibody having(a) a heavy chain variable (VH) region comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOS: 1128, 1129, and 1130,(b) a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOS: 1131, 1132, and 1133; and6) an antibody having(a) a heavy chain variable (VH) region comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOS: 33, 1134, and 35,(b) a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOS: 42, 43, and 44. 2. The antibody of claim 1, wherein the antibody is humanized. 3. The antibody of claim 1, wherein the VH region further comprises: (1) a VH FR1 having an amino acid sequence selected from the group consisting of SEQ ID NOS:51, 105, 55, 115-121, 39, 58, and 895-902;(2) a VH FR2 having an amino acid sequence selected from the group consisting of SEQ ID NOS:52, 106, 56, 122-124, 63, 64, and 323-326;(3) a VH FR3 having an amino acid sequence selected from the group consisting of SEQ ID NOS:53, 107-113, 57, 125-251, 96-98, 292-318, 327-833, 53, 859-882, and 903-1030; and/or(4) a VH FR4 having an amino acid sequence of SEQ ID NO 54 or 320. 4. The antibody of claim 1, wherein the VL region further comprises: (1) a VL FR1 having an amino acid sequence selected from the group consisting of SEQ ID NOS:75, 252, 79, 277-283, 91, 1031-1037, and 1059-1061;(2) a VL FR2 having an amino acid sequence selected from the group consisting of SEQ ID NOS:76, 80, 284, 92, 1038-1044, and 1062-1067;(3) a VL FR3 having an amino acid sequence selected from the group consisting of SEQ ID NOS:77, 276, 81, 285-291, 93, 1049-1055, 1068, and 1069; and/or(4) a VL FR4 having an amino acid of SEQ ID NO:78. 5. The antibody of claim 1, wherein: (i) the VH region comprises the amino acid sequence of SEQ ID NOs: 16, 17, 18, or 19; and(ii) the VL region comprises an amino acid sequence of SEQ ID NOs: 26 or 27. 6. The antibody of claim 1, wherein the antibody is a monoclonal antibody, a recombinant antibody, a fusion protein, an antigen binding fragment, a Fab Fragment, F(ab′)2 fragment, single chain Fv (sFv), diabody, triabody, or minibody. 7. An antibody of claim 1, wherein the antibody is conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent. 8. A method of inhibiting the growth of a cell having cell surface expression of C10orf54 comprising contacting the cell with an effective amount of the composition of claim 1. 9. A method of treating a C10orf54-expressing cancer comprising administering to a subject a therapeutically effective amount of an anti-C10orf54 antibody, or an antibody-drug conjugate comprising an anti-C10orf54 antibody, wherein the antibody is the antibody of claim 1. 10. A method of killing a tumor cell comprising contacting a C10orf54-expressing tumor cell with an amount of an anti-C10orf54 antibody, or antibody-drug conjugate comprising an anti-C10orf54 antibody, effective to kill the tumor cell, wherein the antibody is the antibody of claim 1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (187)
Davies David Huw,GBX ; Boyle Francis Thomas,GBX ; Wardleworth James Michael,GBX ; Kenny Peter Wedderburn,GBX ; Scholes Peter Beverley,GBX ; Matusiak Zbigniew Stanely,GBX, 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Gewirtz Alan M. (Philadelphia PA) Small Donald (Baltimore MD) Civin Curt I. (Baltimore MD), Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein.
Yuzhakov Vadim Vladimirovich ; Sherman Faiz Feisal ; Owens Grover David ; Gartstein Vladimir, Apparatus and method for using an intracutaneous microneedle array.
Anthony Neville J. ; Gomez Robert P. ; Stokker Gerald E. ; Wai John S. ; Williams Theresa M. ; Halczenko Wasyl ; Hutchinson John H. ; Young Steven D. ; Solinsky Kelly M., Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors.
Bikker Jack ; Dobrusin Ellen Myra ; Doherty Annette Marian,FRX ; Drowns Matthew ; Kaltenbronn James Stanley ; Kleinschroth Juergen,DEX ; McNamara Dennis Joseph ; Quin ; III John ; Repine Joseph Thoma, Bicyclic inhibitors of protein farnesyl transferase.
Bikker Jack ; Dobrusin Ellen Myra ; Doherty Annette Marian,FRX ; Drowns Matthew ; Kaltenbronn James Stanley ; Kleinschroth Juergen,DEX ; McNamara Dennis Joseph ; Quin ; III John ; Repine Joseph Thoma, Bicyclic inhibitors of protein farnesyl transferase.
Capon Daniel J. (Hillsborough CA) Weiss Arthur (Mill Valley CA) Irving Brian A. (San Francisco CA) Roberts Margo R. (San Francisco CA) Zsebo Krisztina (Woodside CA), Chimeric chains for receptor-associated signal transduction pathways.
Lee Hye-Jung ; Johnson OluFunmi L. ; Zale Stephen E. ; Tracy Mark A., Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent.
Jean-Fran.cedilla.ois Riou FR; Patrick Mailliet FR; Patricia Vrignaud FR, Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one t.
Cooper Alan B. ; Desai Jagdish A. ; Saksena Anil K. ; Girijavallabhan Viyyoor M. ; Wang James J-S, Compounds useful for inhibition of farnesyl protein transferase.
F George Njoroge ; Arthur G. Taveras ; Ronald J. Doll ; Tarik Lalwani ; Carmen Alvarez ; Stacy W. Remiszewski, Compounds useful for inhibition of farnesyl protein transferase.
Njoroge F George ; Taveras Arthur G. ; Doll Ronald J. ; Lalwani Tarik ; Alvarez Carmen ; Remiszewski Stacy W., Compounds useful for inhibition of farnesyl protein transferase.
Yatvin Milton B. ; Stowell Michael H. B. ; Gallicchio Vincent S. ; Meredith Michael J., Covalent microparticle-drug conjugates for biological targeting.
Beutler Bruce A. (Dallas TX) Peppel Karsten (Dallas TX) Crawford David F. (Irving TX), DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Platz Robert M. ; Patton John S. ; Foster Linda C. ; Eljamal Mohammed,LBX, Dispersible antibody compositions and methods for their preparation and use.
Balazs Endre A. (Ft. Lee NJ) Leshchiner Adolf (Fairview NJ) Larsen Nancy E. (Ridgefield Park NJ), Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same.
Marc Gaston Venet FR; Patrick Rene Angibaud FR; Philippe Muller FR; Gerard Charles Sanz FR, Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives.
Arthur G. Taveras ; Ronald J. Doll ; Alan B. Cooper ; Johan A. Ferreira ; Timothy Guzi ; Dinanath F. Rane ; Viyyoor M. Girijavallabhan ; Cynthia J. Aki ; Jianping Chao ; Carmen Alvarez ; Jo, Farnesyl protein transferase inhibitors.
Timothy Guzi ; Dinanath F. Rane ; Alan K. Mallams ; Alan B. Cooper ; Ronald J. Doll ; Viyyoor M. Girijavallabhan ; Arthur G. Taveras ; Corey Strickland ; Joseph M. Kelly ; Jianping Chao, Farnesyl protein transferase inhibitors.
You Seung Shin KR; Jong Sung Koh KR; Hyun Il Lee KR; Jin Ho Lee KR; Jong Hyun Kim KR; Hyun Ho Chung KR; Kwi Hwa Kim KR; Tae Hwan Kwak KR; Seong Gu Ro KR; In Ae Ahn KR; Tae Saeng Choi KR; Y, Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof.
Bourzat Jean-Dominique,FRX ; Commer.cedilla.on Alain,FRX ; Dereu Norbert,FRX ; Mailliet Patrick,FRX ; Sounigo-Thompson Fabienne,FRX ; Martin Jean-Paul,FRX ; Capet Marc,FRX ; Cheve Michel,FRX, Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments.
Bourzat Jean-Dominique,FRX ; Commer.cedilla.on Alain,FRX ; Dereu Norbert,FRX ; Mailliet Patrick,FRX ; Sounigo-Thompson Fabienne,FRX ; Martin Jean-Paul,FRX ; Capet Marc,FRX ; Cheve Michel,FRX, Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments.
Annette Marian Doherty FR; James Stanley Kaltenbronn ; Daniele Marie Leonard ; Dennis Joseph McNamara ; John Quin, III, Functionalized alkyl and alenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors.
Dobrusin Ellen M. ; Doherty Annette M. ; Kaltenbronn James S. ; Leonard Daniele M. ; McNamara Dennis J. ; Sebolt-Leopold Judith ; Shuler Kevon R., Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase.
Kucherlapati Raju (Darien CT) Koller Beverly H. (Carrboro NC) Smithies Oliver (Chapel Hill NC), Homologous recombination for universal donor cells and chimeric mammalian hosts.
Hawkins Phillip R. (Mountain View CA) Hillman Jennifer L. (San Jose CA) Au-Young Janice (Berkeley CA), Human camp-dependent protein kinase inhibitor homolog.
Lee Hyun Il,KRX ; Koh Jong Sung,KRX ; Lee Jin Ho,KRX ; Jung Won Hee,KRX ; Shin You Seung,KRX ; Chung Hyun Ho,KRX ; Kim Jong Hyun,KRX ; Ro Seong Gu,KRX ; Choi Tae Saeng,KRX ; Jeong Shin Wu,KRX ; Kwak , Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof.
Francis Thomas Boyle GB; Gareth Morse Davies GB; James Michael Wardleworth GB; Jean-Claude Arnould FR, Imidazolyl compounds as inhibitors of farnesyl-protein tranferase.
Morgan Jeffrey R. (Brighton MA) Mulligan Richard C. (Cambridge MA), In vivo introduction and expression of foreign genetic material in epithelial cells.
Alan B. Cooper ; Ronald J. Doll ; Johan A. Ferreira ; Ashit Ganguly ; Viyyoor M. Girijavallabhan ; Arthur G. Taveras ; Jianping Chao ; John J. Baldwin ; Chia-Yu Huang ; Ge Li, Inhibitors of farnesyl-protein transferase.
Anthony Neville J. ; Dinsmore Christopher ; Gomez Robert P. ; Hutchinson John H. ; Wai John S. ; Williams Theresa M. ; Bell Ian M. ; Embrey Mark W. ; Fisher Thorsten E., Inhibitors of farnesyl-protein transferase.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Miyazawa, Kenichi; Sawada, Shuichi; Wakui, Yukio, Magnetoresistive head, manufacture thereof, and magnetic recording/reproducing apparatus with such magnetic head.
Wigler Michael H. ; Sorge Joseph A., Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using.
Calanchi Massimo,ITX ; Zema Marco,ITX ; Brunetti Gabriele,ITX ; Giorgetti Enzo,ITX, Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon.
Huang Grace P. (Miami FL) Rhode Peter R. (Miami FL) Stinson Jeffrey R. (Davie FL) Wong Hing C. (Ft. Lauderdale FL), Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage.
Semiramis Ayral-Kaloustian ; Douglas Bruce Kitchen ; Andrei Shavnya, Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives.
Morrison Sherie L. ; Herzenberg Leonard A. ; Oi Vernon T., Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric.
Stemmer Willem P. C. ; Crameri Andreas, Methods for generating polynucleotides having desired characteristics by iterative selection and recombination.
Johnson Kevin Stuart,GBX ; Winter Gregory Paul,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX ; Waterhouse Peter Michael,AUX, Methods for producing members of specific binding pairs.
McCafferty John,GBX ; Pope Anthony Richard,GBX ; Johnson Kevin Stuart,GBX ; Hoogenboom Henricus Renerus Jacobus Mattheus,GBX ; Griffiths Andrew David,GBX ; Jackson Ronald Henry,GBX ; Holliger Kaspar , Methods for producing members of specific binding pairs.
Cabilly Shmuel ; Heyneker Herbert L. ; Holmes William E. ; Riggs Arthur D. ; Wetzel Ronald B., Methods of producing immunoglobulins, vectors and transformed host cells for use therein.
Boss Michael A. (Slough GBX) Kenten John H. (High Wycombe GBX) Emtage John S. (High Wycombe GBX) Wood Clive R. (Near Fordingbridge GBX), Multichain polypeptides or proteins and processes for their production.
Venkateshwaran Srinivasan ; Fikstad David ; Ebert Charles D., Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Bernstein Howard (Cambridge MA) Morrel Eric (Needham MA) Mathiowitz Edith (Brookline MA) Schwaller Kirsten (Duxbury MA) Beck Thomas R. (Concord MA), Protein microspheres and methods of using them.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Dinsmore Christopher J ; Anthony Neville J. ; Stokker Gerald E. ; Gomez Robert P., Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Targeted gas and gaseous precursor-filled liposomes.
Friend David R. ; Ng Steve ; Sarabia Rafael E. ; Weber Thomas P. ; Geoffroy Jean-Marie, Taste-masked microcapsule compositions and methods of manufacture.
Browne Michael Joseph,GB2 ; Young Peter Ronald ; Shatzman Allan Richard ; Murphy Kay Elizabeth,GB2 ; Chapman Conrad Gerald,GB2 ; Clinkenbeard Helen Elizabeth,GB2, Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins.
Willner David (Hamden CT) Trail Pamela A. (Farmington CT) King H. Dalton (Hamden CT) Hofstead Sandra J. (Middletown CT) Greenfield Robert S. (Wallingford CT) Braslawsky Gary R. (Glastonbury CT), Thioether conjugates.
Norris James ; Clawson Gary ; Westwater Caroline ; Schofield David ; Schmidt Michael ; Hoel Brian ; Dolan Joseph ; Pan Wei-Hua, Tissue-specific and pathogen-specific toxic agents and ribozymes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.